{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:40:27Z","timestamp":1791211227676,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.lungcan.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T09:51:45Z","timestamp":1657878705000},"page":"26-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial"],"prefix":"10.1016","volume":"171","author":[{"given":"Penella","family":"Woll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers","family":"Gaunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3593-2890","authenticated-orcid":false,"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samreen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Mulatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishree","family":"Bhosle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Billingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.lungcan.2022.07.007_b0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jnci\/djp200","article-title":"Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial","volume":"101","author":"Lee","year":"2009","journal-title":"J Natl Cancer Inst."},{"issue":"8","key":"10.1016\/j.lungcan.2022.07.007_b0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.07.007_b0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","article-title":"Immunotherapeutic approaches for small-cell lung cancer","volume":"17","author":"Iams","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2022.07.007_b0020","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet."},{"issue":"8","key":"10.1016\/j.lungcan.2022.07.007_b0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/cancers10080248","article-title":"Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells","volume":"10","author":"Testa","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"56","key":"10.1016\/j.lungcan.2022.07.007_b0030","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","article-title":"DNA damage signalling guards against activated oncogenes and tumour progression","volume":"26","author":"Bartek","year":"2007","journal-title":"Oncogene."},{"key":"10.1016\/j.lungcan.2022.07.007_b0035","doi-asserted-by":"crossref","unstructured":"Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2(9):798-811.","DOI":"10.1158\/2159-8290.CD-12-0112"},{"issue":"9494","key":"10.1016\/j.lungcan.2022.07.007_b0040","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(05)67569-1","article-title":"Small-cell lung cancer","volume":"366","author":"Jackman","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.lungcan.2022.07.007_b0045","doi-asserted-by":"crossref","unstructured":"McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109-8115.","DOI":"10.1158\/0008-5472.CAN-06-0140"},{"issue":"6330","key":"10.1016\/j.lungcan.2022.07.007_b0050","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science."},{"issue":"9","key":"10.1016\/j.lungcan.2022.07.007_b0055","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2022.07.007_b0060","doi-asserted-by":"crossref","unstructured":"Cardnell RJ, Feng Y, Diao L, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013;19(22):6322-6328.","DOI":"10.1158\/1078-0432.CCR-13-1975"},{"issue":"2","key":"10.1016\/j.lungcan.2022.07.007_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.lungcan.2022.07.007_b0070","unstructured":"EuroQol Research Foundation. EQ-5D user guides. Last accessed 07-Feb-2022. https:\/\/euroqol.org\/publications\/user-guides\/."},{"issue":"1","key":"10.1016\/j.lungcan.2022.07.007_b0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1191\/0962280202sm269ra","article-title":"Simultaneous analysis of quality of life and survival data","volume":"11","author":"Billingham","year":"2002","journal-title":"Stat Methods Med Res."},{"key":"10.1016\/j.lungcan.2022.07.007_b0080","doi-asserted-by":"crossref","unstructured":"Pili\u00e9 PG, Gay CM, Byers LA, et al. PARP inhibitors: Extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25(13):3759-3771.","DOI":"10.1158\/1078-0432.CCR-18-0968"},{"issue":"1","key":"10.1016\/j.lungcan.2022.07.007_b0085","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-019-0154-9","article-title":"Advances and perspectives of PARP inhibitors","volume":"8","author":"Yi","year":"2019","journal-title":"Exp Hematol Oncol."},{"key":"10.1016\/j.lungcan.2022.07.007_b0090","doi-asserted-by":"crossref","unstructured":"Lok BH, Gardner EE, Schneeberger VE, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res. 2017;23(2):523-535.","DOI":"10.1158\/1078-0432.CCR-16-1040"},{"issue":"17","key":"10.1016\/j.lungcan.2022.07.007_b0095","doi-asserted-by":"crossref","first-page":"28575","DOI":"10.18632\/oncotarget.15338","article-title":"Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer","volume":"8","author":"Stewart","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.lungcan.2022.07.007_b0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2017.10.006","article-title":"Targeting DNA damage in SCLC","volume":"114","author":"Foy","year":"2017","journal-title":"Lung Cancer."},{"issue":"39","key":"10.1016\/j.lungcan.2022.07.007_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_238473","article-title":"The DNA damaging revolution: PARP inhibitors and beyond","author":"Yap","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"3","key":"10.1016\/j.lungcan.2022.07.007_b0110","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2022.07.007_b0115","doi-asserted-by":"crossref","unstructured":"Farago AF, Yeap BY, Stanzione M, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9(10):1372-1387.","DOI":"10.1158\/2159-8290.CD-19-0582"},{"issue":"23","key":"10.1016\/j.lungcan.2022.07.007_b0120","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2022.07.007_b0125","doi-asserted-by":"crossref","unstructured":"de Bono J, Ramanathan RK, Mina L, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620-629.","DOI":"10.1158\/2159-8290.CD-16-1250"},{"key":"10.1016\/j.lungcan.2022.07.007_b0130","doi-asserted-by":"crossref","unstructured":"Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9(5):646-661.","DOI":"10.1158\/2159-8290.CD-18-1020"},{"issue":"9","key":"10.1016\/j.lungcan.2022.07.007_b0135","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2022.07.007_b0140","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in combination with olaparib in patients with relapsed SCLC: Results from a phase II study","volume":"14","author":"Thomas","year":"2019","journal-title":"J Thorac Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.07.007_b0145","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J Clin Invest."},{"issue":"1","key":"10.1016\/j.lungcan.2022.07.007_b0150","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41467-021-20998-8","article-title":"Histone parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs","volume":"12","author":"Rudolph","year":"2021","journal-title":"Nat Commun."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:00:25Z","timestamp":1759237225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222005475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":30,"alternative-id":["S0169500222005475"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.07.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}